Drugs / HRS4800
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04991909 | Aug 2021 → May 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04862884 | May → Sep 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04573036 | Nov 2020 → Sep 2021 | — | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05318846 | Jan → Feb 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS4800 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05318846 ↗ |
| Route | Oral | “single oral administration” NCT04573036 ↗ |